- Home
- HSTM vs ELVN Comparison
HSTM vs ELVN Comparison
Compare HSTM & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSTM
- ELVN
- Stock Information
- Founded
- HSTM 1990
- ELVN 2016
- Country
- HSTM United States
- ELVN United States
- Employees
- HSTM N/A
- ELVN N/A
- Industry
- HSTM Computer Software: Programming Data Processing
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- HSTM Technology
- ELVN Health Care
- Exchange
- HSTM Nasdaq
- ELVN Nasdaq
- Market Cap
- HSTM 960.2M
- ELVN 1.1B
- IPO Year
- HSTM 2000
- ELVN 2020
- Fundamental
- Price
- HSTM $32.10
- ELVN $19.95
- Analyst Decision
- HSTM Hold
- ELVN Strong Buy
- Analyst Count
- HSTM 2
- ELVN 5
- Target Price
- HSTM $30.00
- ELVN $38.20
- AVG Volume (30 Days)
- HSTM 193.7K
- ELVN 239.7K
- Earning Date
- HSTM 04-21-2025
- ELVN 03-13-2025
- Dividend Yield
- HSTM 0.39%
- ELVN N/A
- EPS Growth
- HSTM 32.31
- ELVN N/A
- EPS
- HSTM 0.66
- ELVN N/A
- Revenue
- HSTM $291,646,000.00
- ELVN N/A
- Revenue This Year
- HSTM $6.51
- ELVN N/A
- Revenue Next Year
- HSTM $5.69
- ELVN N/A
- P/E Ratio
- HSTM $48.65
- ELVN N/A
- Revenue Growth
- HSTM 4.51
- ELVN N/A
- 52 Week Low
- HSTM $23.92
- ELVN $15.96
- 52 Week High
- HSTM $34.24
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- HSTM 43.76
- ELVN 45.06
- Support Level
- HSTM $31.60
- ELVN $20.23
- Resistance Level
- HSTM $32.27
- ELVN $22.12
- Average True Range (ATR)
- HSTM 0.73
- ELVN 1.12
- MACD
- HSTM 0.05
- ELVN 0.02
- Stochastic Oscillator
- HSTM 58.60
- ELVN 10.68
About HSTM HealthStream Inc.
HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.